Pancreatic Cancer Research

ResearcherLund UniversityActive in the last 2 years

Karin Jirström

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2257-5000; OpenAlex author ID A5029764881. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 0, last author 7)
Trials
1
Grants
0
Labs led
1
Collaborators
11
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 2 papers, 1 trial · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Systemic and local decorin levels mirror the clinical course of pancreatic cancer. Last author DOI 10.1002/2056-4538.70066↗
  2. Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in patients with newly diagnosed pancreatic c… Last author DOI 10.1038/s41598-025-22369-5↗
  3. PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer. Last author DOI 10.1002/cjp2.238↗
  4. Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-21-0986↗
  5. Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.32945↗
  6. Hormonal factors and pancreatic cancer risk in women: The Malmö Diet and Cancer Study. Last author DOI 10.1002/ijc.31302↗
  7. Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification. Last author DOI 10.18632/oncotarget.23486↗
  8. Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmö Diet and Cancer Study. Last author DOI 10.1186/s13293-016-0120-8↗
  9. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Co-author DOI 10.3109/0284186x.2015.1075663↗

Trials 1

  1. Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer Study chair NCT03724994↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sofie Olsson Hau · 4 shared papers, 1 shared trial, 2018–2026 · strength 1.03
  2. Karin Leandersson · 3 shared papers, 1 shared trial, 2018–2025 · strength 0.67
  3. Jakob Eberhard · 5 shared papers, 2016–2025 · strength 0.66
  4. Maja Svensson · 2 shared papers, 2025–2026 · strength 0.56
  5. Jacob Elebro · 5 shared papers, 2016–2022 · strength 0.55
  6. Margareta Heby · 3 shared papers, 1 shared trial, 2016–2020 · strength 0.44
  7. Alexandra Petersson · 2 shared papers, 2022–2025 · strength 0.37
  8. Emelie Karnevi · 2 shared papers, 2018–2022 · strength 0.22
  9. Gustav Andersson · 2 shared papers, 2016–2018 · strength 0.22
  10. Sebastian Lundgren · 1 shared paper, 2020 · strength 0.12
  11. Artur Mezheyeuski · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.